We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, a potential best-in-class HDAC inhibitor, ME-401, a highly selective PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor.
MEI Pharma Presents at Needham Healthcare Conference
[ Webcast ]
MEI Pharma Appoints Dr. Christine White as Chairman of the Board
[ December 10, 2015 ]
Click here for our 2015 Annual Review